EDIT · Editas Medicine Inc
United States · RS rating 17 · As of 2026-10-14
| Price | 2.27 USD |
|---|---|
| 1-day change | -7.2% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 17 / 18 / 19 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 28 / 37 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +78.6% |
| Sales growth Q/Q | +228.0% |
| Distance from 52-week high | +45.2% |
| Market cap (USD) | $314.2M |